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The recent clinical successes of immunotherapies such
as anti-PD-1 and anti-CTLA-4 antibody blockade have
re-invigorated the idea that the immune system has the
potential to be a powerful tool to destroy tumors. How-
ever despite ample evidence that these therapies are able
to enhance the efficacy of anti-tumor CD8+ T cell
responses, the association of pro-survival molecules
such as Mcl-1 with this process remains poorly under-
stood. We have previously shown that short-term in
vitro co-culture of human T cells with human-derived
tumor cell lines of various origins can induce the gain
of senescence-like features CD8+ T cells, particularly
the loss of CD27/CD28 expression and the gain of a
potent suppressive function in in vitro suppression
assays. In subsequent studies, we found that IL-7 could
protect T cells from the development of dysfunction/
suppression, and that this process is highly dependent
on the expression of the pro-survival protein Mcl-1. In
the current study we sought to determine whether the
beneficial effects of IL-7 could also be shown in vivo in
a mouse model of head and neck squamous cell carci-
noma (HNSCC). We show that the use of exogenous
IL-7 treatment results in a delay in tumor growth, and
that the combination of IL-7 with other immunothera-
pies, particularly anti-PD-1 antibody blockade, results in
a synergistic response which is better than either therapy
alone. Further, when combined with an adoptive transfer
of TCR transgenic T cells, IL-7 treatment results in
enhanced delay of tumor growth and greater numbers of
tumor-specific T cells in the tumor microenvironment.
Similar to our previous in vitro studies, we further find
that expression of Mcl-1 can have a significant effect on
anti-tumor CD8+ T cells responses. Knock-down of Mcl-
1 expression significantly abrogates the function of
tumor-specific, adoptive-transferred T cells while the
enhancement of Mcl-1 expression also enhances CD8+
function and significantly delays tumor growth. These
data indicate that one benefit of existing immunotherapy
strategies like IL-7 could be in the enhancement of
expression of pro-survival factors like Mcl-1, and those
future treatment strategies which specifically target their
expression could improve anti-tumor immune responses.
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